• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

活的和非活性 CCFM1120 对酒精性肝病的缓解作用:调节肠道微生物群及 Nrf2/HO-1 和 TLR4/MyD88/NF-κB 通路。

The alleviative effects of viable and inactive CCFM1120 against alcoholic liver disease modulation of gut microbiota and the Nrf2/HO-1 and TLR4/MyD88/NF-κB pathways.

机构信息

State Key Laboratory of Food Science and Resources, Jiangnan University, Wuxi, China.

School of Food Science and Technology, Jiangnan University, Wuxi, China.

出版信息

Food Funct. 2024 Aug 27;15(17):8797-8809. doi: 10.1039/d4fo02592j.

DOI:10.1039/d4fo02592j
PMID:39114922
Abstract

Probiotics can alleviate alcoholic liver disease. However, whether inactive counterparts can produce similar outcomes requires further investigation. We investigated the effects of viable (V) and dead (D) CCFM1120 on alcohol-induced ALD mice. The results showed that CCFM1120V and D ameliorated the disease symptoms and intestinal injury. Specifically, these interventions strengthened the intestinal barrier, as evidenced by the increased expression of ZO-1 (zonula occludens 1), occludin, and claudin-1 in the colon and the restored ileal microstructure, including the villi and crypts. In addition, they enhanced the antioxidant capacity of the liver by reducing the production of malondialdehyde and increasing the levels of glutathione and superoxide dismutase. The activation of Nrf2 and HO-1 may be responsible for recovering the antioxidant capacity. Interventions can decrease mouse TNF-α, IL-6 and IL-1β content in serum, probably through the TLR4/MyD88/NF-κB pathway. Furthermore, they possess the ability to restore the quantities of bacteria responsible for producing butyric acid, such as , , , , and . Taken together, CCFM1120V and D apparently can modify the composition of the gut microbiota, foster the gastrointestinal equilibrium, fortify the intestinal barrier, augment the antioxidant capacity of the liver, and effectively shield it from ethanol-induced injury.

摘要

益生菌可缓解酒精性肝病。然而,死菌是否能产生类似的效果仍需进一步研究。本研究考察了活菌(V)和死菌(D)CCFM1120 对酒精性肝损伤(ALD)小鼠的影响。结果表明,CCFM1120V 和 D 改善了疾病症状和肠道损伤。具体而言,这些干预措施增强了肠道屏障,表现为结肠中 ZO-1(闭锁小带蛋白 1)、occludin 和 claudin-1 的表达增加,回肠的微观结构得到恢复,包括绒毛和隐窝。此外,它们通过降低丙二醛的产生和增加谷胱甘肽和超氧化物歧化酶的水平来增强肝脏的抗氧化能力。Nrf2 和 HO-1 的激活可能是恢复抗氧化能力的原因。干预可以降低小鼠血清中 TNF-α、IL-6 和 IL-1β 的含量,可能通过 TLR4/MyD88/NF-κB 途径。此外,它们还具有恢复产生丁酸的细菌数量的能力,如 、 、 、 、 。综上所述,CCFM1120V 和 D 可明显改变肠道微生物群的组成,促进胃肠道平衡,增强肠道屏障,增强肝脏的抗氧化能力,并有效防止乙醇诱导的损伤。

相似文献

1
The alleviative effects of viable and inactive CCFM1120 against alcoholic liver disease modulation of gut microbiota and the Nrf2/HO-1 and TLR4/MyD88/NF-κB pathways.活的和非活性 CCFM1120 对酒精性肝病的缓解作用:调节肠道微生物群及 Nrf2/HO-1 和 TLR4/MyD88/NF-κB 通路。
Food Funct. 2024 Aug 27;15(17):8797-8809. doi: 10.1039/d4fo02592j.
2
Regulation of Gut Microflora by Zhang Attenuates Liver Injury in Mice Caused by Anti-Tuberculosis Drugs.Zhang 调节肠道微生物群可减轻抗结核药物所致的小鼠肝损伤。
Int J Mol Sci. 2023 May 29;24(11):9444. doi: 10.3390/ijms24119444.
3
KLDS1.0344 and KLDS1.0901 Mixture Prevents Chronic Alcoholic Liver Injury in Mice by Protecting the Intestinal Barrier and Regulating Gut Microbiota and Liver-Related Pathways.KLDS1.0344 和 KLDS1.0901 混合物通过保护肠道屏障和调节肠道微生物群及肝脏相关途径来预防小鼠慢性酒精性肝损伤。
J Agric Food Chem. 2021 Jan 13;69(1):183-197. doi: 10.1021/acs.jafc.0c06346. Epub 2020 Dec 22.
4
FOXO4 ameliorates alcohol-induced chronic liver injury via inhibiting NF-κB and modulating gut microbiota in C57BL/6J mice.FOXO4 通过抑制 NF-κB 和调节 C57BL/6J 小鼠肠道微生物群来改善酒精诱导的慢性肝损伤。
Int Immunopharmacol. 2021 Jul;96:107572. doi: 10.1016/j.intimp.2021.107572. Epub 2021 Mar 30.
5
Probiotics suppress LL37 generated rosacea-like skin inflammation by modulating the TLR2/MyD88/NF-κB signaling pathway.益生菌通过调节 TLR2/MyD88/NF-κB 信号通路抑制 LL37 诱导的酒渣鼻样皮肤炎症。
Food Funct. 2024 Aug 27;15(17):8916-8934. doi: 10.1039/d4fo03083d.
6
Effects of taraxasterol against ethanol and high-fat diet-induced liver injury by regulating TLR4/MyD88/NF-κB and Nrf2/HO-1 signaling pathways.蒲公英甾醇通过调节 TLR4/MyD88/NF-κB 和 Nrf2/HO-1 信号通路对乙醇和高脂饮食诱导的肝损伤的作用。
Life Sci. 2020 Dec 1;262:118546. doi: 10.1016/j.lfs.2020.118546. Epub 2020 Oct 6.
7
A polysaccharide from Alhagi honey protects the intestinal barrier and regulates the Nrf2/HO-1-TLR4/MAPK signaling pathway to treat alcoholic liver disease in mice.一种来自骆驼刺多糖的物质可保护肠道屏障,并调节 Nrf2/HO-1-TLR4/MAPK 信号通路,从而治疗小鼠的酒精性肝病。
J Ethnopharmacol. 2024 Mar 1;321:117552. doi: 10.1016/j.jep.2023.117552. Epub 2023 Dec 10.
8
Mycophenolate mofetil attenuates concanavalin A-induced acute liver injury through modulation of TLR4/NF-κB and Nrf2/HO-1 pathways.霉酚酸酯通过调节 TLR4/NF-κB 和 Nrf2/HO-1 通路减轻刀豆蛋白 A 诱导的急性肝损伤。
Pharmacol Rep. 2020 Aug;72(4):945-955. doi: 10.1007/s43440-019-00055-4. Epub 2020 Jan 14.
9
[Mechanism of Tibetan medicine Ershiwuwei Songshi Pills against liver injury induced by acetaminophen in mice based on Keap1/Nrf2 and TLR4/NF-κB p65 signaling pathways].基于Keap1/Nrf2和TLR4/NF-κB p65信号通路探讨藏药二十五味松石丸对小鼠对乙酰氨基酚所致肝损伤的作用机制
Zhongguo Zhong Yao Za Zhi. 2022 Apr;47(8):2049-2055. doi: 10.19540/j.cnki.cjcmm.20211103.707.
10
Phycocyanin Ameliorates Radiation-Induced Acute Intestinal Toxicity by Regulating the Effect of the Gut Microbiota on the TLR4/Myd88/NF-κB Pathway.藻蓝蛋白通过调节肠道微生物群对 TLR4/Myd88/NF-κB 通路的影响来改善辐射诱导的急性肠道毒性。
JPEN J Parenter Enteral Nutr. 2020 Sep;44(7):1308-1317. doi: 10.1002/jpen.1744. Epub 2019 Nov 25.

引用本文的文献

1
36 Mitigates Alcoholic-Associated Liver Disease Through Modulation of Microbiota and AMPK Signaling.36 通过调节微生物群和AMPK信号通路减轻酒精相关性肝病。
Nutrients. 2025 Jul 17;17(14):2340. doi: 10.3390/nu17142340.
2
SBC5-3 suppresses TNF-α-induced inflammatory responses via NF-κB pathway inhibition in intestinal epithelial cells.SBC5 - 3通过抑制肠道上皮细胞中的NF - κB途径来抑制TNF-α诱导的炎症反应。
Front Microbiol. 2025 Jul 8;16:1573479. doi: 10.3389/fmicb.2025.1573479. eCollection 2025.
3
Gut microbiota in liver diseases: initiation, development and therapy.
肝脏疾病中的肠道微生物群:起始、发展与治疗
Front Med (Lausanne). 2025 Jun 4;12:1615839. doi: 10.3389/fmed.2025.1615839. eCollection 2025.